Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.41
-0.06 (-4.08%)
Market open: Aug 12, 2026, 3:37 PM EDT
1.46
-0.01 (-0.68%)
Previous after-hours: Aug 11, 2026, 5:59 PM EDT
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Name | Position |
|---|---|
| Mr. David J. Katzoff | Chief Financial Officer |
| Mr. Henry C. W. Nisser Esq. | Executive VP, General Counsel & Director |
| Mr. Kenneth S. Cragun CPA | Senior Vice President of Finance |
| Mr. Milton Charles Ault III | Founder & Vice Chairman |
| Mr. Stephan Jackman | CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-08-03 | 8-K | az7312618k.htm |
| 2026-07-22 | 10-K | az72426110k.htm |
| 2026-07-21 | 8-K | p7202618k.htm |
| 2026-04-17 | 8-K | p4172668k.htm |
| 2026-03-20 | 8-K | g3202628k.htm |
| 2026-03-11 | 10-Q | z3626110q.htm |
| 2026-03-06 | 8-K | d362618k.htm |
| 2026-02-26 | DEF 14A | i225262def14a.htm |
| 2026-02-09 | PRE 14A | g29260pre14a.htm |
| 2025-12-09 | 10-Q | r12325010q.htm |